Post the Weekly IMS txn numbers here

Quote







"Early verdicts are not final verdicts, so no one is saying Amarin is doomed just two months into the launch of its prescription-grade fish oil pill. But right now, weekly Vascepa prescription growth is decelerating at a time when it should be doing the opposite. The number of patients going back for Vascepa refills is also lower than expected."- yahoo finance article
 






Anonymous said:
"Early verdicts are not final verdicts, so no one is saying Amarin is doomed just two months into the launch of its prescription-grade fish oil pill. But right now, weekly Vascepa prescription growth is decelerating at a time when it should be doing the opposite. The number of patients going back for Vascepa refills is also lower than expected."- yahoo finance article
Click to expand...

This quote is not from a yahoo finance article. It is from a Street.com article from a basher who has been ignored by Amarin management because they see him for what he is. He has a vendetta against Amarin and will not let it go. He has been proven many times before to be wrong and he will be in this case as well.
 



The Vascepa launch sucks-already the growth rate is flattening.No major pharma company wants to partner with Amarin
Total Vascepa prescriptions were 1,240, up 14% from the week of March 8. Numerically, Vascepa scripts are growing but the rate of growth has dropped for four weeks straight. Week-over-week script growth was 33% for the week ended Feb. 22, down to 14% for the week of March 15.
 



Anonymous said:
The Vascepa launch sucks-already the growth rate is flattening.No major pharma company wants to partner with Amarin
Total Vascepa prescriptions were 1,240, up 14% from the week of March 8. Numerically, Vascepa scripts are growing but the rate of growth has dropped for four weeks straight. Week-over-week script growth was 33% for the week ended Feb. 22, down to 14% for the week of March 15.
Click to expand...

Further to your points, at this stage of the launch, we should be seeing stronger numerical growth as the prescriber base should be growing. Either the initial prescribers are not continuing to prescribe, or there is a problem in getting additional physicians to prescribe the product beyond those that are early adopters.
 



name a drug launched in the last two years that has done better. Thats right there are none. This drug is doing well and will only do better as managed care covers it.

say what you will. but the truth is the truth. look how the others drugs, especially in cardio are doing. this is a stand out. just time is all it needs.
 



1 week doesn't make a trend and these are not complete numbers. Expect the growth to keep up just fine. customers are joining the flow, number of prescribers are jumping every week as are pbms. big pharma is going to be hovering, we will see if they bite or wait for snda approval.
 



If the launch was doing so well the stock would not be near its 52 week low and big pharma would be looking at amarin as an aquisition. Does Vescepa cause AEs that include delusional thoughts?
 



Anonymous said:
name a drug launched in the last two years that has done better. Thats right there are none. This drug is doing well and will only do better as managed care covers it.

say what you will. but the truth is the truth. look how the others drugs, especially in cardio are doing. this is a stand out. just time is all it needs.
Click to expand...

Almost every drug has done better. This one is not doing well. Take a look at the stock price.
 
Last edited by a moderator:




Write your reply...
Top Bottom
Back
Quote